Advertisement
China Sky One Medical's Chief Executive Officer, Mr. Yan-qing Liu, andChief Financial Officer, Mr. Stanley Hao will participate in the NDR to meetwith institutional investors and equity analysts from August 4 to August 5 inHong Kong and on August 6 in Singapore.
Advertisement
"This NDR represents our commitment to maintain communication withinvestors and better understand their expectations," said Mr. Yan-qing Liu,Chairman and CEO of China Sky One Medical. "We will continue this effort bypursuing best practices investor relations activities as we work to buildlasting value to our shareholders."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.The Company engages in the manufacturing, marketing and distribution ofpharmaceutical, medicinal and diagnostic products. Through its wholly-ownedsubsidiaries, Harbin Tian Di Ren Medical Science and Technology Company("TDR"), Harbin First Bio-Engineering Company Limited ("First"), HeilongjiangTianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin ChuangPharmaceutical Company ("Jin Chuang") the Company manufactures and distributesover-the-counter pharmaceutical products, which make up its major revenuesource. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constituteforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements can be identified by the useof forward- looking terminology such as "believe," "expect," "may," "will,""should," "project," "plan," "seek," "intend," or "anticipate" or the negativethereof or comparable terminology. Such statements typically involve risks anduncertainties and may include financial projections or information regardingthe non-deal roadshow. Actual results could differ materially from theexpectations reflected in such forward-looking statements as a result of avariety of factors, including the risks associated with the effect of changingeconomic conditions in The People's Republic of China, variations in cash flow,reliance on collaborative retail partners and on new product development,variations in new product development, risks associated with rapidtechnological change, and the potential of introduced or undetected flaws anddefects in products, and other risk factors detailed in reports filed with theSecurities and Exchange Commission from time to time.For more information, please contact: Company Contact: China Sky One Medical, Inc. Mr. Stanley Hao, CFO Tel: +86-451-5399-4069 Email: [email protected] Investor Relations Contact: CCG Investor Relations Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: [email protected] Web: http://www.ccgirasia.com
SOURCE China Sky One Medical, Inc.
